The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Live Attenuated Vaccines Market Through 2030?
The live attenuated vaccines market size has demonstrated robust growth in recent years. This market is projected to expand from $25.95 billion in 2025 to $28.52 billion in 2026, registering a compound annual growth rate (CAGR) of 9.9%. The historical growth can be attributed to factors such as the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.
The live attenuated vaccines market size is projected to experience substantial growth in the upcoming years. It will grow to $41.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period can be attributed to factors such as demand for booster vaccinations, risks posed by emerging infectious diseases, expansion of cold chain infrastructure, increased global health funding, and advancements in next-generation vaccine platforms. Prominent trends throughout the forecast period include the expansion of national immunization programs, a rising demand for pediatric vaccination, improvements in vaccine stability and storage, a heightened focus on pandemic preparedness, and the ongoing development of multivalent vaccines.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp
What Important Drivers Are Powering The Live Attenuated Vaccines Market Growth?
An anticipated expansion in the live attenuated vaccines market is driven by the growing occurrence of infectious diseases. These diseases are characterized as illnesses stemming from detrimental microorganisms, including bacteria, viruses, fungi, or parasites, which possess the capability to transmit either directly or indirectly among individuals, animals, or environments. The escalating rate of international travel facilitates the accelerated dissemination of infectious diseases, enabling pathogens to traverse geographical boundaries more rapidly than current containment strategies can manage. Live attenuated vaccines play a crucial role in preventing infectious diseases by eliciting a robust immune reaction through attenuated pathogens, thereby guaranteeing sustained immunity and curbing the spread of illnesses. As an illustration, the World Health Organization, an intergovernmental body based in Switzerland, reported in March 2025 that an estimated 10.8 million individuals globally contracted TB in 2023, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the expanding incidence of infectious diseases is fueling the development of the live attenuated vaccines market.
How Is The Live Attenuated Vaccines Market Examined Through Segment Analysis?
The live attenuated vaccines market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Multivalent
2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated
3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users
Subsegments:
1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines
2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines
Which Trends Are Supporting The Evolution Of The Live Attenuated Vaccines Market?
Leading companies within the live attenuated vaccines market are prioritizing the development of advanced products, such as single-dose vaccines, to boost immunization efficiency and improve patient adherence. These single-dose vaccines provide enduring immunity with just one injection, eliminating the necessity for multiple doses. This advancement simplifies the vaccination process for both patients and healthcare providers, thereby enhancing convenience and accessibility. For example, in November 2023, Valneva SE, a France-based biotech company focused on infectious disease vaccines, revealed the launch of IXCHIQ, which had received approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This product is the world’s first live-attenuated chikungunya vaccine indicated for adults aged 18 and older. This approval holds considerable importance as IXCHIQ marks the world’s first licensed vaccine for chikungunya, addressing a previously unmet medical requirement for protection against this mosquito-borne viral disease, which can lead to severe fever, joint and muscle pain, and various other symptoms.
Which Firms Are Competing In The Live Attenuated Vaccines Market?
Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals
Access The Complete Live Attenuated Vaccines Market Report:
https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report
Which Area Represents The Largest Portion Of The Live Attenuated Vaccines Market?
North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Live Attenuated Vaccines Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp
Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company
Inactivated Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Veterinary Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model